Reaves W H & Company Has Cut Its South Jersey Ind (SJI) Stake; 4 Analysts Are Bullish PTC Therapeutics, Inc. (PTCT) Last Week

February 15, 2018 - By Marie Mckinney

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. PTC Therapeutics had 35 analyst reports since July 31, 2015 according to SRatingsIntel. On Friday, October 16 the stock rating was maintained by RBC Capital Markets with “Outperform”. The firm has “Buy” rating by Citigroup given on Friday, November 11. The firm has “Hold” rating by RBC Capital Markets given on Monday, January 29. The company was maintained on Wednesday, July 5 by RBC Capital Markets. RBC Capital Markets downgraded the shares of PTCT in report on Wednesday, February 24 to “Sector Perform” rating. As per Thursday, November 16, the company rating was upgraded by J.P. Morgan. Jefferies downgraded the shares of PTCT in report on Wednesday, November 25 to “Underperform” rating. Wedbush maintained the stock with “Outperform” rating in Wednesday, February 24 report. As per Friday, June 30, the company rating was maintained by Cowen & Co. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Neutral” rating by Credit Suisse on Tuesday, July 26. See PTC Therapeutics, Inc. (NASDAQ:PTCT) latest ratings:

29/01/2018 Broker: RBC Capital Markets Rating: Hold Reinitiate
16/11/2017 Broker: J.P. Morgan Rating: Hold New Target: $15.0 Upgrade
16/11/2017 Broker: JP Morgan Old Rating: Underweight New Rating: Neutral Upgrade
26/10/2017 Broker: Bank of America Rating: Sell New Target: $14.0 Downgrade
25/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $15.0 Maintain
09/10/2017 Broker: J.P. Morgan Rating: Sell Downgrade
09/10/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
29/09/2017 Broker: Barclays Capital Rating: Hold New Target: $15.0
26/09/2017 Broker: J.P. Morgan Rating: Hold Maintain
26/09/2017 Broker: Credit Suisse Rating: Buy New Target: $25.0

Reaves W H & Company Inc decreased South Jersey Ind (SJI) stake by 8.48% reported in 2017Q3 SEC filing. Reaves W H & Company Inc sold 16,726 shares as South Jersey Ind (SJI)’s stock rose 5.23%. The Reaves W H & Company Inc holds 180,625 shares with $6.24M value, down from 197,351 last quarter. South Jersey Ind now has $2.10B valuation. The stock increased 0.06% or $0.01 during the last trading session, reaching $26.4. About 178,273 shares traded. South Jersey Industries, Inc. (NYSE:SJI) has risen 23.64% since February 15, 2017 and is uptrending. It has outperformed by 6.94% the S&P500.

Reaves W H & Company Inc increased Pinnacle West Cap Corp Com (NYSE:PNW) stake by 14,750 shares to 607,433 valued at $51.37M in 2017Q3. It also upped Williams Partners LP Com Unit (ACMP) stake by 250,000 shares and now owns 445,000 shares. American Water Works (NYSE:AWK) was raised too.

Among 7 analysts covering South Jersey Industries (NYSE:SJI), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. South Jersey Industries had 27 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of South Jersey Industries, Inc. (NYSE:SJI) earned “Equal-Weight” rating by Morgan Stanley on Thursday, August 10. The firm earned “Neutral” rating on Monday, January 9 by Guggenheim. On Tuesday, June 28 the stock rating was downgraded by Janney Capital to “Neutral”. The stock of South Jersey Industries, Inc. (NYSE:SJI) earned “Buy” rating by Hilliard Lyons on Thursday, August 31. Hilliard Lyons upgraded the shares of SJI in report on Monday, August 10 to “Underperform” rating. The rating was maintained by Morgan Stanley with “Equal-Weight” on Tuesday, February 13. Williams Capital Group downgraded it to “Hold” rating and $34 target in Wednesday, November 23 report. The firm has “Hold” rating given on Monday, September 18 by Williams Capital Group. The rating was downgraded by Hilliard Lyons on Friday, November 6 to “Underperform”. The firm has “Equal-Weight” rating given on Monday, November 13 by Morgan Stanley.

Analysts await South Jersey Industries, Inc. (NYSE:SJI) to report earnings on February, 22. They expect $0.41 EPS, down 2.38% or $0.01 from last year’s $0.42 per share. SJI’s profit will be $32.54 million for 16.10 P/E if the $0.41 EPS becomes a reality. After $-0.05 actual EPS reported by South Jersey Industries, Inc. for the previous quarter, Wall Street now forecasts -920.00% EPS growth.

Investors sentiment decreased to 1.24 in Q3 2017. Its down 0.10, from 1.34 in 2017Q2. It dropped, as 14 investors sold SJI shares while 52 reduced holdings. 16 funds opened positions while 66 raised stakes. 54.81 million shares or 0.93% more from 54.30 million shares in 2017Q2 were reported. Profund Advisors Ltd Liability holds 16,889 shares or 0.02% of its portfolio. Sterling Capital Ltd Com reported 65,220 shares stake. Old Republic reported 485,000 shares. Paloma Prns Commerce holds 0.01% or 18,190 shares in its portfolio. First LP invested in 0.05% or 614,172 shares. Ubs Asset Americas Incorporated has invested 0% in South Jersey Industries, Inc. (NYSE:SJI). Citigroup holds 0% or 18,934 shares in its portfolio. Gsa Cap Prns Llp invested 0.02% in South Jersey Industries, Inc. (NYSE:SJI). Next Fincl Grp holds 0.04% of its portfolio in South Jersey Industries, Inc. (NYSE:SJI) for 4,080 shares. Murphy Mgmt, New Jersey-based fund reported 6,650 shares. Crow Point Partners Ltd Liability Corporation has invested 1.81% in South Jersey Industries, Inc. (NYSE:SJI). Symons Cap holds 27,182 shares. Ls Investment holds 5,133 shares or 0.01% of its portfolio. 292,759 are owned by Wellington Mgmt Gp Llp. Teachers Retirement Sys Of The State Of Kentucky holds 69,032 shares or 0.03% of its portfolio.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company has market cap of $1.00 billion. The companyÂ’s lead product is Translarna , for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It currently has negative earnings. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.

The stock decreased 0.33% or $0.08 during the last trading session, reaching $24.17. About 200,762 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since February 15, 2017 and is uptrending. It has outperformed by 87.81% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>